Clinical study on therapeutic efficacy and mechanism of all-trance-retinoid acid in refractory immune thrombocytopenia patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002424

Enrollment

Unknown

Registered

2012-07-19

Start date

2012-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

immune thrombocytopenia

Interventions

Experimental Group:All-trance retinoid acid + Danazol

Comparator Group:Danazol

Eligibility

Sex/Gender

All

Age

18 Years to 82 Years

Inclusion criteria

Inclusion criteria: 1. Primary ITP confirmed by excluding other supervened causes of thrombocytopenia; 2. Failure to achieve at least response or loss of response after splenectomy; 3. Need of treatment(s)(including, but not limited to, low dose of corticosteroids) to minimize the risk of clinically significant bleeding; 4. 18 years older.

Exclusion criteria

Exclusion criteria: 1. Secondary thrombocytopenia; 2. Complicated with sever cardio-cerebrovascular diseases; 3. Unable to do blood routine test for the sake of time, distance, economic issues or other reasons.

Design outcomes

Primary

Measure	Time frame
Platelet count;	—

Secondary

Measure	Time frame
megakaryocyte count;Megakaryocyte ploidy analysis;	—

Countries

China

Contacts

Public ContactXiao-hui Zhang

zhangxh100@sina.com+86 13522338836

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026